Targeted Pharmacotherapy for Refractory Metastatic Colorectal Cancer

Refractory metastatic colorectal cancer remains a major clinical challenge, with limited efficacy of conventional cytotoxic regimens in patients who have progressed beyond standard lines of therapy. Targeted pharmacotherapy seeks to exploit specific molecular vulnerabilities within tumour cells, combining nucleoside analogues with precision agents or monoclonal antibodies to overcome resistance mechanisms. Trifluridine/tipiracil (TAS-102) has emerged as an oral backbone in this setting, exerting cytotoxicity through DNA incorporation of trifluridine and sustained exposure ensured by thymidine phosphorylase inhibition. Concurrent targeting of angiogenesis or growth-factor signalling pathways—through agents such as bevacizumab or EGFR inhibitors—has demonstrated synergistic activity in preclinical models and clinical cohorts. Recent advances in genomic profiling have identified predictive biomarkers that can refine patient selection, enabling a move towards precision medicine in heavily pretreated metastatic colorectal cancer.

Research from Nature Portfolio

Recent studies have shown that specific KRAS codon G12 mutations predict a lack of survival benefit from trifluridine/tipiracil. Integrating whole-genome analyses with large clinical trials, researchers observed that patients harbouring KRASG12 mutations derived minimal overall-survival advantage from TAS-102, whereas those with KRASG13 mutations experienced significant prolongation of survival. Functional assays in isogenic cell lines and patient-derived organoids confirmed that KRASG12 mutations confer resistance to FTD-based genotoxicity, highlighting the necessity of genomic stratification when tailoring pharmacotherapy for refractory metastatic colorectal cancer.

Targeted Pharmacotherapy for Refractory Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in targeted pharmacotherapy for refractory metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Refractory metastatic colorectal cancer: Disease that has progressed despite standard chemotherapy and targeted treatments.

Trifluridine/tipiracil (TAS-102): Oral combination of the thymidine analogue trifluridine and thymidine phosphorylase inhibitor tipiracil, enhancing DNA incorporation and cytotoxicity.

KRASG12 mutation: Point mutation at codon 12 of the KRAS gene, often associated with resistance to certain chemotherapies.

FGFR4 p.G388R polymorphism: Genetic variant in the fibroblast growth factor receptor 4 gene linked to altered drug sensitivity.

Bevacizumab: Monoclonal antibody targeting vascular endothelial growth factor (VEGF) to inhibit tumour angiogenesis.

References

1. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nature Medicine (2023).
2. Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment. Journal of Translational Medicine (2024).
3. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncology Reports (2014).
4. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncology Reports (2015).
5. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer (2019).
6. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Investigational New Drugs (2017).
7. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open (2021).